Merus to Participate in a Panel Discussion at Citi's 17th Annual BioPharma Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology firm, announced that CEO Bill Lundberg will participate in a panel at Citi's 17th Annual BioPharma Conference on September 8, 2022, at 2:40 p.m. ET. This event highlights the company's innovative work in developing multispecific antibodies, including Biclonics® and Triclonics®. A live webcast will be available on the company’s investor page, and an archive of the presentation will be accessible for a limited time post-event.
For more details, visit Merus’ website and social media channels.
Details
News Market Reaction – MRUS
The recorded move for MRUS in the trading session of this news was +3.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a panel discussion at Citi's 17th Annual BioPharma Conference on Thursday, September 8, 2022 at 2:40 p.m. ET.
The webcast of the panel discussion will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.